{
    "ticker": "PRPO",
    "name": "Precipio, Inc.",
    "description": "Precipio, Inc. is a biotechnology company focused on the development and commercialization of innovative diagnostic technologies and solutions for the medical community. Founded in 2013, Precipio leverages advanced technology to provide high-quality, accurate, and timely results for healthcare providers and patients. The company specializes in cancer diagnostics, offering a range of services including next-generation sequencing (NGS) and proprietary diagnostic tests that aid in the early detection and treatment of cancer. Through its advanced testing platform, Precipio aims to improve patient outcomes and enhance the efficiency of cancer diagnosis and treatment. The company is dedicated to expanding its diagnostic offerings and continuously innovating to meet the evolving needs of the healthcare industry. Precipio's commitment to precision medicine positions it as a valuable partner for medical professionals seeking reliable diagnostic solutions. With a focus on patient-centric care, Precipio is pioneering methods that empower healthcare providers to make informed decisions based on precise data, ultimately striving to revolutionize cancer diagnostics and treatment planning.",
    "industry": [
        "Biotechnology",
        "Healthcare"
    ],
    "headquarters": "Newark, New Jersey, USA",
    "founded": "2013",
    "website": "https://www.precipiodx.com",
    "ceo": "Ilan Danieli",
    "social_media": {
        "twitter": "https://twitter.com/PrecipioDx",
        "linkedin": "https://www.linkedin.com/company/precipio"
    },
    "investor_relations": "https://ir.precipiodx.com",
    "key_executives": [
        {
            "name": "Ilan Danieli",
            "position": "CEO"
        },
        {
            "name": "David Natan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Diagnostic Services",
            "products": [
                "Next-Generation Sequencing",
                "Proprietary Cancer Tests"
            ]
        }
    ],
    "seo": {
        "meta_title": "Precipio, Inc. | Innovative Cancer Diagnostics",
        "meta_description": "Explore Precipio, Inc., a leader in cancer diagnostics offering advanced testing solutions. Learn about our mission to enhance patient outcomes through precision medicine.",
        "keywords": [
            "Precipio",
            "Cancer Diagnostics",
            "Biotechnology",
            "Precision Medicine",
            "Next-Generation Sequencing"
        ]
    },
    "faq": [
        {
            "question": "What is Precipio known for?",
            "answer": "Precipio is known for its innovative cancer diagnostic solutions and advanced testing technologies."
        },
        {
            "question": "Who is the CEO of Precipio?",
            "answer": "Ilan Danieli is the CEO of Precipio, Inc."
        },
        {
            "question": "Where is Precipio headquartered?",
            "answer": "Precipio is headquartered in Newark, New Jersey, USA."
        },
        {
            "question": "What types of products does Precipio offer?",
            "answer": "Precipio offers diagnostic services including next-generation sequencing and proprietary cancer tests."
        },
        {
            "question": "When was Precipio founded?",
            "answer": "Precipio was founded in 2013."
        }
    ],
    "competitors": [
        "EXAS",
        "NTRA",
        "RGEN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "NVS"
    ]
}